切换至 "中华医学电子期刊资源库"

中华脑血管病杂志(电子版) ›› 2025, Vol. 19 ›› Issue (06) : 463 -466. doi: 10.3877/cma.j.issn.1673-9248.2025.06.001

专家论坛

急性缺血性卒中再灌注联合脑细胞保护治疗的策略
徐元麒, 杨珊珊, 张忠玲()   
  1. 150001 黑龙江 哈尔滨,哈尔滨医科大学附属第一医院神经内科
  • 收稿日期:2025-11-07 出版日期:2025-12-01
  • 通信作者: 张忠玲
  • 基金资助:
    黑龙江省重点研发计划(创新基地)项目(JD24D004)

Strategies for combining reperfusion therapy with brain cytoprotective therapy in acute ischemic stroke

Yuanqi Xu, Shanshan Yang, Zhongling Zhang()   

  1. Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
  • Received:2025-11-07 Published:2025-12-01
  • Corresponding author: Zhongling Zhang
引用本文:

徐元麒, 杨珊珊, 张忠玲. 急性缺血性卒中再灌注联合脑细胞保护治疗的策略[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(06): 463-466.

Yuanqi Xu, Shanshan Yang, Zhongling Zhang. Strategies for combining reperfusion therapy with brain cytoprotective therapy in acute ischemic stroke[J/OL]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2025, 19(06): 463-466.

急性缺血性卒中的核心治疗目标在于挽救缺血半暗带。再灌注治疗虽然能恢复缺血脑组织血流灌注,但“无效再通”现象仍较为普遍,提示单纯血管再通难以阻断缺血-再灌注脑损伤。脑细胞保护治疗作为再灌注的一种重要补充策略,旨在通过多靶点干预减轻再灌注相关损害并促进神经功能恢复。基于近年来的高质量循证研究,本文述评急性缺血性卒中再灌注联合脑细胞保护治疗的研究进展,重点探讨药物性与非药物性脑细胞保护策略的最新证据及临床应用价值,分析多阶段综合干预在改善神经功能预后中的作用与前景,为优化急性缺血性卒中再灌注后脑细胞保护体系提供参考。

The core therapeutic goal of acute ischemic stroke is to salvage the ischemic penumbra. Although reperfusion therapy restores cerebral blood flow, the phenomenon of "futile recanalization" remains common, indicating that vascular recanalization alone cannot fully prevent ischemia-reperfusion brain injury. As an essential complementary strategy to reperfusion, brain cytoprotection therapy aims to mitigate reperfusion-related damage and enhance neurological recovery through multi-target interventions. This review summarizes recent advances in combined reperfusion and brain cytoprotection therapy for acute ischemic stroke based on high-quality clinical evidence, focusing on the latest findings and clinical applicability of pharmacological and non-pharmacological protective strategies. It also discusses the potential role and prospects of integrated multi-phase interventions in improving neurological outcomes, offering insights for optimizing brain cytoprotection strategies following reperfusion therapy in acute ischemic stroke.

1
Nie X, Leng X, Miao Z, et al. Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke [J]. Stroke, 2023, 54(3): 873-881.
2
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023 [J]. 中华神经科杂志, 2024, 57(6): 523-559.
3
Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial [J]. Lancet, 2022, 400(10347): 161-169.
4
Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial [J]. Lancet, 2023, 401(10377): 645-654.
5
Li S, Gu H, Li H, et al. Reteplase versus alteplase for acute ischemic stroke [J]. N Engl J Med, 2024, 390(24): 2264-2273.
6
Li S, Gu H, Feng B, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial [J]. Lancet Neurol, 2025, 24(1): 33-41.
7
Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-guided thrombolysis for stroke with unknown time of onset [J]. N Engl J Med, 2018, 379(7): 611-622.
8
Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke [J]. N Engl J Med, 2019, 380(19): 1795-1803.
9
Albers GW, Jumaa M, Purdon B, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection [J]. N Engl J Med, 2024, 390(8): 701-711.
10
Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy [J]. N Engl J Med, 2024, 391(3): 203-212.
11
Zhou Y, He Y, Campbell BCV, et al. Alteplase for acute ischemic stroke at 4.5 to 24 hours: the HOPE randomized clinical trial [J]. JAMA, 2025, 334(9): 788-797.
12
Yan S, Zhou Y, Lansberg MG, et al. Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours [J]. N Engl J Med, 2025, 392(13): 1288-1296.
13
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct [J]. N Engl J Med, 2018, 378(1): 11-21.
14
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging [J]. N Engl J Med, 2018, 378(8): 708-718.
15
Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular thrombectomy for large ischemic strokes [J]. N Engl J Med, 2023, 388(14): 1259-1271.
16
Huo X, Ma G, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct [J]. N Engl J Med, 2023, 388(14): 1272-1283.
17
Tao C, Nogueira RG, Zhu Y, et al. Trial of endovascular treatment of acute basilar-artery occlusion [J]. N Engl J Med, 2022, 387(15): 1361-1372.
18
Jovin TG, Li C, Wu L, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion [J]. N Engl J Med, 2022, 387(15): 1373-1384.
19
Kaesmacher J, Cavalcante F, Kappelhof M, et al. Time to treatment with intravenous thrombolysis before thrombectomy and functional outcomes in acute ischemic stroke: a Meta-analysis [J]. JAMA, 2024, 331(9): 764-777.
20
Qiu Z, Li F, Sang H, et al. Intravenous tenecteplase before thrombectomy in stroke [J]. N Engl J Med, 2025, 393(2): 139-150.
21
Writing CFTP, Pearl I. Intra-arterial alteplase after successful endovascular reperfusion in acute stroke: the PEARL randomized clinical trial [J]. JAMA, 2025, 334(19): 1728-1739.
22
Miao Z, Luo G, Song L, et al. Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial [J]. JAMA, 2025, 334(7): 582-591.
23
Hou X, Huang J, Wang L, et al. Intra-arterial tenecteplase after successful reperfusion in large vessel occlusion stroke: a randomized clinical trial [J]. JAMA Neurol, 2025, 82(9): 895-904.
24
Savitz SI, Baron J, Fisher M. Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era [J]. Stroke, 2019, 50(4): 1026-1031.
25
Lyden P, Buchan A, Boltze J, et al. Top priorities for cerebroprotective studies-A paradigm shift: report from STAIR XI [J]. Stroke, 2021, 52(9): 3063-3071.
26
逯丹, 陈玮琪, 王雅平, 等. 缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明 [J]. 中国卒中杂志, 2024, 19(8): 938-955.
27
Wang C, Gu H, Dong Q, et al. Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol Ⅱ (TASTE-2): a multicentre randomised controlled trial [J]. Stroke Vasc Neurol, 2024, 9(6): 730-737.
28
冯洁, 刘泽宇, 樊屹殊. 缺血性卒中脑细胞保护临床实践中国专家共识 [J]. 国际神经病学神经外科学杂志, 2025, 52(2): 1-7.
29
Wang A, Jia B, Zhang X, et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial [J]. JAMA Neurol, 2023, 80(8): 851-859.
30
Zheng Z, Li Y, Yang S, et al. Role of human urinary kallikrein in reducing progressive ischemic stroke among acute ischemic stroke patients with concurrent hypertension and diabetes: a hospital-based retrospective cohort study [J]. Front Neurol, 2025, 16: 1520309.
31
Yang Q, Guo C, Yue C, et al. Methylprednisolone as adjunct to endovascular thrombectomy for large-vessel occlusion stroke: the MARVEL randomized clinical trial [J]. JAMA, 2024, 331(10): 840-849.
32
Huang Z, Hu M, Zhang P, et al. Intra-arterial selective hypothermia for acute ischemic stroke neuroprotection: A multicenter pilot trial in China [J]. PLoS Med, 2025, 22(7): e1004668.
33
Guo Z, Abuduxukuer R, Wang C, et al. Remote ischaemic conditioning improves outcomes of ischaemic stroke treated by endovascular thrombectomy: the SERIC-EVT trial [J]. Eur Heart J, 2025: ehaf570.
34
Li W, Lan J, Wei M, et al. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial [J]. Lancet, 2025, 405(10477): 486-497.
35
Chen H, Zhang N, Cui Y, et al. A randomized trial of Trendelenburg position for acute moderate ischemic stroke [J]. Nat Commun, 2023, 14(1): 2592.
[1] 石豆豆, 王新星, 王向阳, 刘震洋, 曾淑娟, 仝海波. 急性前循环大血管闭塞机械取栓的研究进展[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(02): 112-116.
[2] 郑鸥, 黄信全, 李学杰, 黄年平, 谭支文. 血浆MCP-1、YKL-40与单侧症状性MCA-M1段重度狭窄或闭塞的AIS患者脑侧支循环不良的关系[J/OL]. 中华脑科疾病与康复杂志(电子版), 2025, 15(02): 115-121.
[3] 王益, 许璐. 依达拉奉右莰醇治疗急性缺血性卒中的疗效及对患者血清Trx、NLR水平的影响[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(06): 359-364.
[4] 陶栎, 张月辉, 王相明. 急性缺血性卒中院前急救体系的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(01): 56-60.
[5] 朱建华, 刘茜茜, 郑玉琳, 朱水兵. 脑循环治疗仪联合综合康复训练对急性缺血性脑卒中恢复期的效果观察[J/OL]. 中华脑科疾病与康复杂志(电子版), 2022, 12(06): 349-354.
[6] 林枫, 张鸿运, 贺迎坤, 李天晓. 围术期NLR变化可预测急性前循环大血管闭塞性卒中取栓患者的临床预后[J/OL]. 中华介入放射学电子杂志, 2022, 10(04): 396-403.
[7] 姚富远, 陈芳兰, 邓哲. 非溶栓急性缺血性卒中患者早期神经功能恶化的影响因素分析[J/OL]. 中华卫生应急电子杂志, 2022, 08(04): 193-198.
[8] 刘锦, 张婕, 刘松, 马丹, 韩剑虹. 2019—2022年昆明市二、三级医院卒中中心急性缺血性卒中静脉溶栓指标分析[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(05): 397-403.
[9] 付志勇, 马欣, 董静, 杜祥颖, 尹春琳. 压力感受器分布动脉的粥样硬化总负荷对卒中后新监测到的心房颤动的影响[J/OL]. 中华脑血管病杂志(电子版), 2025, 19(03): 175-183.
[10] 董坤, 陈海恋, 王景. 血清CircRNA_0003694与老年急性缺血性卒中患者卒中后认知损害的关系[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(03): 230-235.
[11] 梁文雯, 李征, 万敏, 骆佳莹, 贾伟华. 急性缺血性卒中再灌注治疗后出血转化的研究进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(01): 71-80.
[12] 辛伽伦, 袁兴运, 刘志勤, 师瑞, 蒋锋, 刘锋昌, 李伟旺, 张恒, 郭强, 何剑波, 姚力. 药物洗脱支架在急性大脑中动脉粥样硬化闭塞性卒中患者急诊血管成形术中的临床疗效[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(06): 539-544.
[13] 袁兴运, 陈万红, 鱼丽萍, 姚力. 以Wallenberg综合征起病的椎动脉颅外段闭塞介入治疗探讨[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(04): 394-399.
[14] 张运, 裴月红, 傅瑜. 急性缺血性卒中静脉溶栓治疗进展[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(02): 83-88.
[15] 季秋虹, 柯开富, 沈俊涛, 徐飞, 张红, 徐添, 刘可威, 高建林, 巢宝华. 开展“中国千县万镇卒中识别行动”后区域脑卒中医疗服务流程改进的研究[J/OL]. 中华脑血管病杂志(电子版), 2022, 16(02): 84-87.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?